INTENSITY THERAPEUTICS, INC.
Business
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company developing INT230-6, an intratumoral cancer therapeutic comprising cisplatin, vinblastine sulfate, and an amphiphilic molecule (SHAO) that enables drug dispersion within tumors. The company's proprietary DfuseRx discovery platform creates novel formulations to overcome tumor microenvironment barriers and enable localized drug delivery with systemic immune activation. INT230-6 is in Phase 3 development for metastatic soft tissue sarcoma and Phase 2 for presurgical triple-negative breast cancer, with completed Phase 1/2 data in heavily pretreated advanced cancers across multiple solid tumor types.
Summary from 10-K filed 2026-03-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 7 | 10 | 5 | 5 | |
| General and administrative | 5 | 6 | 4 | 2 | |
| Total operating expenses | 12 | 17 | 8 | 8 | |
| Loss from operations | −12 | −17 | −8 | −8 | |
| Interest income | 180,000 | 314,000 | 324,000 | 2,000 | |
| Other income, net | 186,000 | 3,000 | — | — | |
| Net loss | −12 | −16 | −11 | −8 | |
| Loss per share, basic (in dollars per share) | −8.56 | −29.24 | −1.38 | −2.22 | |
| Loss per share, diluted (in dollars per share) | −8.56 | −29.24 | −1.38 | −2.22 | |
| Weighted average number of shares of common stock, basic (in shares) | 1 | 556,279 | 9 | 3 | |
| Weighted average number of shares of common stock, diluted (in shares) | 1 | 556,279 | 9 | 3 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 3 | 9 | 1 | — | |
| Prepaid expenses and other current assets | 788,000 | 773,000 | 688,000 | — | — | |
| Total current assets | 13 | 3 | 15 | 1 | — | |
| Right-of-use asset, net | 96,000 | 122,000 | 147,000 | 139,000 | — | |
| Other assets | 1 | 1 | 2 | 167,000 | — | |
| Total assets | 14 | 5 | 17 | 2 | — | |
| Accounts payable | 583,000 | 1 | 3 | 603,000 | — | |
| Accrued expenses | 2 | 508,000 | 891,000 | 2 | — | |
| Lease liability, current portion | 31,000 | 28,000 | 20,000 | 143,000 | — | |
| Total current liabilities | 2 | 2 | 4 | 7 | — | |
| Lease liability, net of long-term portion | 79,000 | 110,000 | 138,000 | 0 | — | |
| Total liabilities | 2 | 2 | 4 | 7 | — | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, par value $.0001. Authorized shares of 15,000,000 as of both December 31, 2025 and 2024, respectively. None issued and outstanding as of both December 31, 2025 and 2024. | 0 | 0 | 0 | 0 | — | |
| Common stock, par value $.0001. Authorized shares of 135,000,000 as of both December 31, 2025 and 2024, respectively. Issued and outstanding shares of 2,524,475 and 604,915 as of December 31, 2025 and 2024, respectively. | 0 | 0 | 1,000 | 0 | — | |
| Additional paid-in capital | 90 | 70 | 64 | 24 | — | |
| Accumulated deficit | −78 | −67 | −51 | −39 | — | |
| Total stockholders equity | 12 | 3 | 13 | −15 | −9 | |
| Total liabilities and stockholders equity | 14 | 5 | 17 | 2 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Change in carrying value of right-of-use asset | 26,000 | 25,000 | 147,000 | 179,000 | |
| Stock-based compensation expense | 2 | 3 | 1 | 1 | |
| Stock issued in exchange for services | 0 | 51,000 | 0 | — | |
| Accrued interest on marketable debt securities | 0 | −134,000 | −197,000 | 0 | |
| Prepaid expenses, other current assets, and other assets | −13,000 | 301,000 | −2 | 53,000 | |
| Accounts payable, accrued expenses and other liabilities | 360,000 | −2 | 2 | 704,000 | |
| Net cash used in operating activities | −9 | −15 | −7 | −5 | |
| Purchase of marketable debt securities | 0 | −3 | −15 | 0 | |
| Redemption of marketable debt securities | 0 | 9 | 9 | 0 | |
| Net cash provided by investing activities | 0 | 6 | −6 | 0 | |
| Proceeds from Public Offerings | 5 | 0 | 22 | 0 | |
| Proceeds from exercise of options and warrants | 56,000 | 321,000 | 50,000 | 0 | |
| Net cash provided by financing activities | 19 | 3 | 20 | 2 | |
| Net increase (decrease) in cash and cash equivalents | 9 | −6 | 7 | −3 | |
| Common stock issued in exchange for services | 0 | 51,000 | 5 | 0 | |
| Warrants issued to underwriter in connection with stock issuance | 1 | 1 | 1 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is INTENSITY THERAPEUTICS, INC.'s CIK number?
INTENSITY THERAPEUTICS, INC.'s SEC CIK number is 0001567264 (1567264). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find INTENSITY THERAPEUTICS, INC.'s SEC filings?
All of INTENSITY THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did INTENSITY THERAPEUTICS, INC. last report earnings?
INTENSITY THERAPEUTICS, INC. (INTS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001567264-26-000047). This is INTENSITY THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is INTENSITY THERAPEUTICS, INC.'s most recent earnings 8-K?
INTENSITY THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001567264-26-000047. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View INTENSITY THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →